Skip To Main Content
Le contenu de ce site web est exclusivement réservé aux professionnels de santé en Belgique et au Luxembourg.
Campus
  • Aires thérapeutiques
  • Ressources
Campus
  • Aires thérapeutiques
  • Ressources
View Full Results

Articles

Sort by

Filtres

Réinitialiser
  • Aires thérapeutiques

The observational ORION study

Real-world safety and effectiveness of insulin glargine 300 U/mL in participants with type 2 diabetes who fast during Ramadan.

Explorer

Glycaemic Targets and Vascular Complications in Type 2 Diabetes: What Are the Thresholds?

Summary of Zoungas S, et al. Diabetologia. 2012;55:636–643.

Explorer

Approach for patients with coronary artery disease (CAD): focus on LDL-C control

Explorer

Le pouvoir de réduire le chaos lié au VRS

Explorer

When to Initiate Basal Insulin?

Practical Guidance based on the 2022 ADA/EASD Guidelines.

Explorer

Approach for patients with peripheral artery disease (PAD) + T2DM: focus on LDL-C control

Explorer

Cardiovascular diseases (CVDs) are the leading cause of death globally

Explorer

Is Glycemic Control the Key to Preventing Long-term Complications in Type 2 Diabetes?

(Based on the study: Stratton IM, et al. BMJ. 2000;321(7258):405-12).

Explorer

How Does Glycaemic Control Impact Complications in Type 2 Diabetes?

Summary of The UK Prospective Diabetes Study (UKPDS).

Explorer

Why is Glycaemic Control in Type 2 Diabetes Still a Challenge?

Summary of Aschner P, et al. Diabetologia. 2020;63(4):711-721.

Explorer

What is TTP? A rare, life-threatening medical emergency

Early diagnosis and treatment of Thrombotic thrombocytopenic purpura (TTP) can help prevent the high risk of early deaths.

Explorer

When to suspect TTP?

TTP is rare and presents similarly to other thrombotic microangiopathies (TMAs), making it difficult to diagnose.

Explorer